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Abstract
Background: Dengue viruses (DENVs) and Japanese encephalitis virus (JEV) have significant cross-reactivity in serological
assays; the clinical implications of this remain undefined. An improved understanding of whether and how JEV immunity
modulates the clinical outcome of DENV infection is important as large-scale DENV vaccine trials will commence in areas
where JEV is co-endemic and/or JEV immunization is routine.
Methods and Findings: The association between preexisting JEV neutralizing antibodies (NAbs) and the clinical severity of
DENV infection was evaluated in a prospective school-based cohort in Thailand that captured asymptomatic, non-
hospitalized, and hospitalized DENV infections. Covariates considered included age, baseline DENV antibody status, school
of attendance, epidemic year, and infecting DENV serotype. 942 children experienced at least one DENV infection between
1998 and 2002, out of 3,687 children who were enrolled for at least one full year. In crude analysis, the presence of JEV NAbs
was associated with an increased occurrence of symptomatic versus asymptomatic infection (odds ratio [OR] = 1.55, 95% CI:
1.08–2.23) but not hospitalized illness or dengue hemorrhagic fever (DHF). The association was strongest in children with
negative DENV serology (DENV-naive) (OR = 2.75, 95% CI: 1.12–6.72), for whom the presence of JEV NAbs was also
associated with a symptomatic illness of longer duration (5.4 days for JEV NAb+ versus 2.6 days for JEV NAb-, p = 0.048). JEV
NAbs were associated with increased DHF in younger children with multitypic DENV NAb profiles (OR = 4.05, 95% CI: 1.18 to
13.87). Among those with JEV NAbs, the association with symptomatic illness did not vary by antibody titer.
Interpretation: The prior existence of JEV NAbs was associated with an increased probability of symptomatic as compared
to asymptomatic DENV illness. These findings are in contrast to previous studies suggesting an attenuating effect of
heterologous flavivirus immunity on DENV disease severity.
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Introduction
The dengue viruses (DENV) and Japanese encephalitis virus
(JEV) are closely-related members of the virus family Flaviviridae.
DENV and JEV co-circulate in the Indian subcontinent and in
Southeast Asia, where they are important causes of human disease
and mortality. The co-occurrence of JEV and DENV has been
documented in Thailand since 1969, when severe epidemics of
each were observed in the Chiang Mai valley region [1]. There is
no licensed DENV vaccine and vector control efforts have been
largely ineffective in containing transmission. While inactivated
and live-attenuated JEV vaccines are licensed for use in humans,
vaccination does not interrupt the primary JEV transmission cycle
involving pigs, waterfowl, and Culicine mosquitoes [2]. Despite
reported high levels of JEV vaccination (estimated to be 84% in
1998 and 98% in 2008), infections continue to be detected in
Thailand each year [3].
JEV and DENV exhibit significant serological cross-reactivity,
which can complicate assessment of the relative burdens of each in
co-endemic areas and their possible interactions [4,5]. There exists
limited, inconclusive evidence regarding the clinical implications
of prior JEV exposure or JEV vaccination and the severity of
subsequent DENV infection. Using observed interactions between
DENV serotypes as an analogy, JEV/DENV cross-reactive
immunity may possibly be protective [6], detrimental [7], or
inconsequential. Hoke et al. reported that recipients of inactivated
JEV vaccine (JEVAX) experienced a non-significant decrease in
the occurrence of DHF relative to placebo during the first two
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years after vaccination and that, among DHF patients, vaccinees
experienced milder disease [8]. There was no evidence of an
association between JEV vaccination and the occurrence of DHF
in a study of hospitalized DENV patients in Bangkok [9]. There
has been no reported increase in adverse events following live-
attenuated DENV vaccination of JEV-immune volunteers [10,11].
However, DENV vaccine recipients have demonstrated height-
ened and broadened DENV antibody responses and antibody
responses of longer duration in the setting of preexisting
heterologous flavivirus immunity [12–14].
Two human studies have provided evidence of a possible
protective effect of the opposite sequence; i.e., DENV exposure
followed by JEV infection. Burke et al found decreased clinical
severity in JEV-infected hospitalized patients with higher levels of
flavivirus-cross-reactive IgG in Thailand, presumed to be
attributable to prior DENV infection [15]. Hammon observed
that following the eradication of DENV from Guam in 1945, a
subsequent large JEV epidemic in 1947 caused illness in those who
were less likely to have been exposed to DENV previously, namely
young children and adult expatriates[16,17].
Animal and in vitro studies of cross-reactivity between various
combinations of flaviviruses suggest that the nature of the
interactions need not be bidirectional and that the influence of a
given virus may vary by serotype and even strain [18]. There exists
ample evidence that DENV infection may be enhanced in vitro
with heterotypic DENV antibodies [19] and also with antibodies
to non-DENV flaviviruses, including JEV [20]. However, a study
using sera from JEV-immune Thai individuals found no evidence
of enhancement of DENV-2 infection in vitro [21]. Animal studies
have suggested a protective role of DENV immunity upon JEV
challenge in mice [22] and a protective role of WNV immunity
upon subsequent challenge with another member of the JEV
antigen complex in a variety of animal models [23–26]. In
summary, there has been evidence of both protective and
detrimental interactions between heterologous flaviviruses; the
mechanisms and epidemiological implications of these associations
remain unclear.
Potential interactions between flaviviruses are important for
public health because wild-type JEV continues to co-circulate with
DENV in Southeast Asia, the area with the highest burden of
DENV illness, and JEV vaccination coverage in this region is high.
As DENV vaccines advance toward licensure and implementation
in co-endemic regions, an improved understanding of what
constitutes protective immunity with DENV exposure is necessary.
Given ambiguous findings from prior studies, we examined how
preexisting JEV immunity influenced the clinical severity of
subsequent DENV infection using data from a prospective school-
based cohort study in Thailand [27,28]. The availability of
information on asymptomatic DENV infections as well as
outpatient and hospitalized dengue cases provided a unique
opportunity to assess these interactions.
Methods
Ethics Statement
The prospective cohort study that generated these data was co-
administered by the University of Massachusetts and the Armed
Forces Research Institute of Medical Sciences (AFRIMS) for the
years 1998–2002. TE, AR, DL, and AN were involved in the
design and conduct of the cohort study, for which all subjects
provided written informed consent. ST and RG are among the
lead scientists presently managing the Department of Virology at
AFRIMS, where specimens and data from this study are
maintained. The lead author, KA, used only preexisting
demographic and laboratory data for the purposes of this
retrospective analysis.
The cohort study was approved by the Human Use Review and
Regulatory Agency of the Office of the Army Surgeon General,
the Institutional Review Board of the University of the
Massachusetts Medical School, and the Ethical Review Board of
the Ministry of Public Health, Thailand. Secondary data analysis
for the purpose of this publication was approved by the
Institutional Review Board at Emory University.
Study Population
Data were collected during a five-year, school-based, prospec-
tive cohort study for DENV infections in children in Northern
Thailand. The study design and methods have been described
previously [27,28]. Briefly, the study was conducted in Kam-
phaeng Phet Province from 1998–2002. In January 1998, 2,214
children were recruited from grades 1 through 5 at twelve primary
schools. New participants were enrolled from the 1st grade class in
January of each year and eligible participants were re-enrolled.
The numbers of children enrolled at the start of the active
surveillance period each year were 2,044 in 1998; 1,915 in 1999;
2,203 in 2000; 2,011 in 2001; and 1,759 in 2002. A total of 3,687
children were enrolled for at least one year during the study
period, with an average of 2.9 years of follow-up per child. At
enrollment, the children or their parents were asked about prior
JEV vaccination and age of vaccination.
Study Methods
Serum samples were collected for dengue serology four times
each year (January, June, August, and November). All serological
and virological testing was performed at AFRIMS in Bangkok,
Thailand. Active case surveillance of the participants was
conducted from June 1 to November 1, with potential illnesses
identified based on absence from school, visit to a school nurse or
public health clinic, or admission to the hospital. Absent students
Author Summary
Dengue viruses (DENVs) and Japanese encephalitis virus
(JEV) have significant cross-reactivity in serological assays,
but the possible clinical implications of this remain poorly
understood. Interactions between these flaviviruses are
potentially important for public health because wild-type
JEV continues to co-circulate with DENV in Southeast Asia,
the area with the highest burden of DENV illness, and JEV
vaccination coverage in this region is high. In this study,
we examined how preexisting JEV neutralizing antibodies
(NAbs) influenced the clinical severity of subsequent DENV
infection using data from a prospective school-based
cohort study in Thailand that captured a wide range of
clinical severities, including asymptomatic, non-hospital-
ized, and hospitalized DENV infections. We found that the
prior existence of JEV NAbs was associated with an
increased occurrence of symptomatic versus asymptom-
atic DENV infection. This association was most notable in
DENV-naives, in whom the presence of JEV NAbs was also
associated with an illness of longer duration. These
findings suggest that the issue of heterologous flavivirus
immunity and DENV infection merits renewed attention
and interest and that DENV vaccine developers might
incorporate detailed assessments of preexisting immunity
to non-DENV flaviviruses and histories of vaccination
against non-DENV flaviviruses in evaluating DENV vaccine
safety and efficacy.
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were visited by village health workers and evaluated with a
symptom questionnaire and an oral temperature. Acute blood
samples were obtained for students with a history of fever within 7
days of fever onset, as were 14-day convalescent samples.
Characterization of Symptomatic Illnesses
Acute and convalescent blood specimens from incident febrile
illnesses were tested using immunoglobulin M (IgM) and G (IgG)
enzyme immunoassays for DENV and JEV. Acute DENV
infections were defined serologically as a DENV-specific IgM
level $ 40 units and with DENV-IgM . JEV-IgM. The infecting
DENV serotype was identified from acute blood specimens using
serotype-specific reverse-transcriptase polymerase chain reaction
(RT-PCR) or virus isolation. Symptomatic infections were defined
as a documented history of febrile illness with virologic or serologic
evidence of acute DENV infection. Charts of hospitalized children
were independently reviewed and classified as DF or DHF and
assigned a severity grade following WHO criteria [29]. If a child
experienced a febrile DENV illness but did not meet the criteria
for DHF, they were characterized as having DF.
Table 1. Cohort characteristics associated with symptomatic DENV illness.
# Infections *
(% of Total) % Symptomatic p-value **
Total infections 569 44.5%
Infection Severity
Asymptomatic 316 (55.5%) –
DF 217 (38.1%) – –
DHF 36 (6.3%) –
JEV NAb Status
Negative 265 (46.6%) 46.0%
Positive 214 (37.6%) 57.0% 0.021
Missing 90 (15.8%) 10.0%
Age (years)
7-9 216 (38.0%) 47.7%
10-12 341 (59.9%) 42.2% 0.423
13-15 10 (1.8%) 50.0%
Missing 2 (0.4%) 50.0%
Gender
Male 275 (48.3%) 42.5%
Female 292 (51.3%) 46.2% 0.699
Missing 2 (0.4%) 50.0%
School (12 total)
Range (Min – Max) 5–139 32.3–80.0% 0.618
Epidemic Year
1998 168 (29.5%) 42.3%
1999 133 (23.4%) 42.9%
2000 46 (8.1%) 26.1% 0.032
2001 173 (30.4%) 51.4%
2002 49 (8.6%) 49.0%
Pre-Infection DENV NAb Profile
DENV-Naı̈ve 83 (14.6%) 55.4%
Monotypic 74 (13.0%) 59.5% 0.131
Multitypic 322 (56.6%) 47.8%
Missing 90 (15.8%) 10.0%
Reported JEV Vaccination
Yes 311 (54.7%) 40.8%
Can’t recall 108 (19.0%) 51.9% 0..119
No 149 (26.1%) 36.3%
Missing 1 (0.2%) 0.0%
*Refers to first-detected DENV infections in the cohort that occurred during the active surveillance period each year (June 1–November 1) and had neutralizing antibody
data available
**Statistical tests considered the association between variables of interest and the occurrence of symptomatic versus asymptomatic infection. p-values were obtained
using the Pearson chi-square test for categorical variables, with a= 0.05 as the level of significance. ‘Missing’ categories were not included in statistical comparisons.
doi:10.1371/journal.pntd.0001311.t001
Japanese Encephalitis Immunity and Dengue Illness
www.plosntds.org 3 October 2011 | Volume 5 | Issue 10 | e1311
The duration of illness was derived from home visit data and
hospitalization records. For non-hospitalized illnesses, the duration
of illness was the length of time from the date of school absence or
clinic visit to the date of the last home visit at which the child
exhibited symptoms consistent with DENV infection. For
hospitalized illnesses, the duration of illness was the pre-
hospitalization time plus the time in the hospital.
Characterization of Asymptomatic Infections
Routine specimens were tested for the presence of hemagglu-
tination inhibiting (HI) antibodies against DENV-1 – DENV-4
and JEV using standard methods [30]. The reference virus strains
were DENV-1 (Hawaii), DENV-2 (New Guinea ‘C’), DENV-3
(H87), DENV-4 (H241), and JEV (Nakayama). Asymptomatic
DENV infections were defined as a four-fold or greater rise in
hemagglutination inhibition (HI) titers for any of the four DENV
serotypes between two consecutive routine serum samples and
without a concurrent four-fold rise in JEV HI titers, or with a
concurrent four-fold rise in JEV HI titers but with higher HI titers
for any DENV serotype than for JEV.
Characterization of DENV and JEV Antibody Status
Plaque reduction neutralization titers (PRNTs) were obtained
for pre-infection samples using standard methods [31]. Briefly,
LLC-MK2 cell monolayers were infected with DENV1 – DENV4
and JEV in the presence of serial dilutions of heat-inactivated
patient plasma. The reference virus strains were: DENV-1
(16007), DENV-2 (16681), DENV-3 (16562), DENV-4 (1036),
and JEV (Nakayama), for which the sources and passage histories
have been previously described [32]. The lowest dilution of serum
tested was 1:10 (corresponding to a final dilution of 1:20 when
combined with an equal volume of DENV); the dilutions and titers
Table 2. Factors associated with JEV seropositivity among those experiencing dengue (DENV) infection.
# Infections * (% of Total) % JEV positive p-value **
Total DENV infections 479 44.7%
DENV Infection Severity
Asymptomatic 235 (49.1%) 39.1%
DF 211 (44.1%) 50.2% 0.017
DHF 33 (6.9%) 48.5%
Age (years)
7–9 185 (38.6%) 43.2%
10–12 285 (59.5%) 44.9% 0.209
13–15 8 (1.7%) 75.0%
Missing 1 (0.2%) 100.0%
Gender
Male 232 (48.4%) 44.8%
Female 246 (51.4%) 44.7% 0.667
Missing 1 (0.2%) 100.0%
School (12 total)
Range (Min – Max) 4 – 127 13.3% – 75.0% 0.004
Dengue Epidemic Year
1998 145 (30.3%) 36.6%
1999 104 (21.7%) 57.7%
2000 32 (6.7%) 50.0% 0.021
2001 159 (33.2%) 42.1%
2002 39 (8.1%) 46.2%
Pre-Infection DENV NAb Profile
DENV-Naı̈ve 83 (17.3%) 54.2%
Monotypic 74 (15.4%) 25.7% 0.001
Multitypic 322 (67.2%) 46.6%
Reported JEV Vaccination
Yes 259 (54.1%) 51.0%
Can’t recall 95 (19.8%) 38.9% 0.012
No 124 (25.9%) 36.3%
Missing 1 (0.2%) 0.0%
*Refers to first-detected DENV infections in the cohort that occurred during the active surveillance period each year (June 1 – November 1) and had neutralizing
antibody data available.
**Statistical tests considered the association between variables of interest and the presence or absence of JEV NAbs in the pre-infection sample. p-values were obtained
using the Pearson chi-square test for categorical variables, with a= 0.05 as the level of significance. ‘Missing’ categories were not included in statistical comparisons.
doi:10.1371/journal.pntd.0001311.t002
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reported herein refer to the initial serum dilution. The
concentration of patient plasma that resulted in a 50% reduction
in plaque formation was calculated using log probit regression.
The reciprocal titer of this dilution was defined as the PRNT50. A
PRNT50 ,10 was defined as undetectable or ‘negative’ and a titer
$10 as ‘positive.’ PRNT assays were performed for asymptomatic
infections only if the child had not missed school during the
observation period. This was done in an attempt to exclude missed
symptomatic DENV illnesses that could have been misclassified as
asymptomatic seroconversions.
Children were grouped into three categories of DENV
immunity based upon their pre-infection DENV antibody profiles:
DENV-naı̈ve (pre-infection PRNT50,10 for all DENV serotypes),
DENV-monotypic (pre-infection PRNT50 $10 for a single DENV
serotype), and DENV-multitypic (pre-infection PRNT50 $10 for
two or more DENV serotypes). To attempt to discern cross-
reactive immunity from serotype-specific immunity, we further
stratified DENV-multitypics according to mean age of infection,
with the logic that older children would have had more time to
experience multiple DENV infections and generate multiple
serotype-specific responses, while younger children with multitypic
profiles would, on average, reflect more cross-reactivity. Preexist-
ing JEV immunity was dichotomized as JEV-positive (pre-infection
PRNT50$10) and JEV-negative (pre-infection PRNT50,10).
Inferring the Infecting Serotype
By definition, acute phase blood samples were not available
from children with asymptomatic DENV infections for direct
detection of the infecting virus. Approximately one-quarter of
symptomatically infected individuals were RT-PCR negative,
likely because the acute specimen was drawn when the child was
no longer viremic. Based upon evidence that DENV transmission
in this community is highly clustered, we assumed that the
serotypes detected among RT-PCR positive cases attending a
given school during a given epidemic year were representative of
the serotypes causing asymptomatic and RT-PCR negative
symptomatic infections at that school [33,34]. To minimize the
possible biases inherent to this assumption, imputation of an
individual’s unknown infecting serotype using community-level
data was performed only for children residing in communities that
had a single serotype detected during that epidemic year. If more
than one serotype was detected at a given school during a given
year, the infecting serotype was left as missing.
JEVAX – Description and Administration
The JEV vaccine used in Thailand and throughout Southeast
Asia, JEVAX, is a formalin-inactivated, mouse brain-derived JEV
vaccine. The first dose of JEVAX in Thailand is administered
concurrently with the diphtheria/tetanus/pertussis vaccine at 18
months of age. A second dose is administered 1 to 4 weeks later
and a third (booster) dose is administered at 30 to 36 months of
age. The seroconversion rates with JEVAX in Thai children have
been estimated to be 50% following primary vaccination, 64–80%
following secondary vaccination, and 100% following receipt of
the third dose [35]. Based upon these observations of suboptimal
seroconversion rates with the two dose regimen, the third dose was
added to the Expanded Program for Immunization (EPI) regimen
in Thailand in 2000.
History of JEV Vaccination Programs in Kamphaeng Phet
A Phase III trial of JEVAX was conducted in 1984 in
Kamphaeng Phet, Thailand, which demonstrated favorable
efficacy [8]. JEVAX began to be slowly incorporated into the
EPI in Thailand in 1988 and became part of Kamphaeng Phet’s
EPI in 1992. Vaccination histories for the cohort study were
obtained by self-report and subsequent verification with clinic or
family documents was not possible. However, given the ages of the
children enrolled (five to fourteen years of age) and the timing of
the study (1998 to 2002), it is likely that the majority of children
enrolled in the cohort study would have received two doses of JEV
vaccine. Younger children would likely have been vaccinated as
infants, as part of the EPI program, and older children would
likely have been vaccinated during the large ‘‘catch-up’’
vaccination programs taking place in the province in the 1990s.
The JEVAX vaccine strain in use during the 1990s in Thailand
was the Nakayama strain, the country has since switched to the
Beijing strain.
Statistical Analyses
Bivariate analyses were performed using chi-square testing for
categorical variables and ANOVA or nonparametric testing for
continuous variables. Logistic regression models for symptomatic
versus asymptomatic infection were constructed using SAS’
GENMOD procedure, accounting for the clustering of observa-
tions by school. The best model was then chosen by backward
regression. Analyses were performed using SAS software, version 8
(SAS Institute, Cary, NC), SPSS for Windows version 10.0 (SPSS
Inc., Chicago, IL), and R version 2.10.1 (R Foundation for
Statistical Computing, Vienna, Austria).
Results
A total of 942 children experienced at least one DENV infection
between 1998 and 2002, out of 3,687 children who were enrolled
for at least one full year. While some experienced multiple DENV
infections during their enrollment, analyses are restricted to the
first detected infection for each child. Further characterization of
infections as symptomatic or asymptomatic was limited to those
569 cases that occurred within the active surveillance period (June
1 – November 1). Three-hundred-sixteen (56%) of these infections
were asymptomatic and 253 (44%) were symptomatic. Of the
symptomatic cases, 217 (86%) were DF and 36 (14%) were DHF
(Table 1). No deaths were attributed to DENV infection.
Factors Associated with Symptomatic Illness
Children with JEV NAbs were more likely to experience
symptomatic infection than children without JEV NAbs (57%
versus 46%, p = 0.021 by x2 testing, Table 1). Of the 569 first
Table 3. Unadjusted associations of DENV illness severity and
JEV antibody status.
# Infections % JEV Positive OR (95% CI) {
Symptomatic 244 50.0% 1.55 (1.08–2.23)
Asymptomatic 235 39.1%
Hospitalized 48 43.8% 0.96 (0.53–1.75)
Non-hospitalized * 431 44.8%
DHF 33 48.5% 1.18 (0.58–2.39)
Non-DHF ** 446 44.4%
*Non-hospitalized infections incorporate both non-hospitalized DF and
asymptomatic seroconversions.
**Non-DHF infections incorporate both non-hospitalized and hospitalized DF
and asymptomatic seroconversions.
{P-values were calculated using the Mantel-Haenzel chi-square statistic.
doi:10.1371/journal.pntd.0001311.t003
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detected DENV infections, 479 had pre-infection DENV and JEV
neutralizing antibody titer information available for analysis
(84.2%). 90% of the missing NAb data were associated with
asymptomatic infections, for reasons described above.
There were no differences by age, gender, or school in the
proportions of infections that were symptomatic. The proportion
of infections that were symptomatic varied by year, from 26% in
2000 to 51% in 2001 (p = 0.032, by x2 testing across all strata of
epidemic year). There were no differences in the proportion
symptomatic by pre-infection DENV antibody status. There was
no difference in the proportion symptomatic by reported JEV
vaccination history and, among those reporting a history of
vaccination, no difference in the time between vaccination and the
first detected infection (mean6SD 5.0162.22 years for asympto-
matics, 4.9362.11 for symptomatics).
Factors Associated with JEV Positivity
Children developing DF were most likely to be JEV NAb
positive, those experiencing asymptomatic infection the least (50%
versus 39%, p = 0.017, by x2 testing across all strata of infection
severities) (Table 2). There were no differences in the proportions
of children that were JEV NAb positive by age or gender. The
proportion JEV NAb positive varied by school and year. DENV-
naives were most likely to be JEV NAb positive (54%), then
DENV-multitypics (47%), then DENV-monotypics (26%)
(p = 0.001 by x2 testing). Those reporting a history of JEV
vaccination were more likely to be JEV NAb positive (46% versus
31% p = 0.012 by x2 testing). Among those reporting a history of
vaccination, there was no difference in time since vaccination
(mean6SD 5.0162.27 years for JEV NAb positives, 4.9662.19
for JEV NAb negatives).
Associations of JEV NAb Positivity with DENV Illness
JEV NAb positivity was associated with an increase in the odds
of symptomatic infection in unadjusted analysis (OR = 1.55, 95%
CI: 1.08 to 2.23) (Table 3). There were no significant differences
in the occurrence of hospitalized illness or the occurrence of
DHF.
Individuals with JEV NAbs were more likely to experience
symptomatic DENV infection for all strata of preexisting DENV
immunity, though this association was strongest and significant
only for DENV-naives (OR = 2.75, 95% CI: 1.12 to 6.72)
(Figure 1a). The association was non-significant and weakest for
children with DENV-monotypic immunity prior to infection.
Younger and older children with DENV-multitypic immunity had
approximately the same increased odds of symptomatic infection
with JEV NAbs; neither association was significant.
The directions of the associations between JEV NAbs and
hospitalized illness (Figure 1b) and JEV NAbs and DHF (Figure 1c)
were not consistent across strata of preexisting DENV immunity
and the associations were largely non-significant. The association
between JEV NAbs and DHF was significant only for younger
DENV-multitypics, who had increased odds of DHF with JEV
NAbs (OR = 4.05, 95% CI: 1.18 to 13.87).
Duration of Illness
The presence of JEV NAbs was associated with an increased
duration of DENV illness in DENV-naives (5.70 versus 2.69 days,
p = 0.045) (Table 4). For DENV-monotypics and multitypics, no
difference in the duration of illness was observed.
Titer of JEV NAbs
Among those with JEV NAbs prior to infection, there was no
difference in the geometric mean titer between asymptomatically
and symptomatically infected individuals (p = 0.45 by Mann-
Whitney U test, Figure 2). The distributions of the titers were
similar.
Role of Infecting DENV Serotype
The greatest number of RT-PCR-positive illnesses in the cohort
was associated with DENV-2; the highest proportion of hospital-
ized infections was observed with DENV-3 (Figure 3a). The
infecting DENV serotype was unknown for all asymptomatic
infections and for 25.2% of symptomatic infections. 40.0% of
children missing serotype data resided in communities with a
single serotype in circulation the year of their infection and were
therefore eligible for imputation. The probability of symptomatic
infection was increased with JEV NAbs for all DENV serotypes,
but the association was not significant for any serotype in subgroup
analysis (Figure 3b). Limiting the comparisons to symptomatic,
RT-PCR positive infections (with no imputation), the direction of
the association between JEV NAbs and hospitalized illness was
highly variable (Figure 3c). DENV-3 infection in the setting of
preexisting JEV NAbs was associated with decreased hospitalized
illness (15.0% hospitalized with JEV NAbs versus 46.7%
hospitalized without, p = 0.004 by x2 test).
Multivariate Model of JEV NAb Positivity and
Symptomatic DENV Infection
The positive, significant association between the presence of
JEV NAbs and symptomatic infection remained after controlling
Figure 1. Clinical severity of dengue infections by strata of preexisting DENV and JEV immunity. The proportions of dengue (DENV)
infections resulting in symptomatic illness (1a), hospitalized illness (1b), and dengue hemorrhagic fever (1c) are shown. Data are stratified by
preexisting DENV immunity (naı̈ve [DENV -], monotypic [DENV 1+], multitypic older and younger than 10 years of age [DENV .1+]) and preexisting
Japanese encephalitis virus (JEV) neutralizing antibodies (NAbs) (positive [+] or negative [-]). The JEV NAb positive groups are indicated by hash lines
for each stratum of DENV immunity. Odds ratios (ORs) estimate the odds of being experiencing the disease severity of interest (dengue hemorrhagic
fever [DHF], hospitalized illness [Hosp], or symptomatic illness [Sx]) in the presence of JEV NAbs over the odds of experiencing the disease severity of
interest in the absence of JEV NAbs. Values in parentheses indicate the 95% confidence intervals for the ORs. Error bars indicate the 95% confidence
intervals for proportions.
doi:10.1371/journal.pntd.0001311.g001
Table 4. Duration of DENV illness (days) by JEV NAb status.
Mean duration of illness in
days (SD) * JEV NAb - JEV NAb+ p-value **
All symptomatic infections 4.51 (5.28) 4.89 (5.66) 0.591
DENV-Naives 2.69 (1.74) 5.70 (5.68) 0.045
DENV-Monotypic 5.52 (7.62) 4.75 (5.79) 0.756
DENV-Multitypic 4.51 (4.58) 4.60 (5.68) 0.915
*Duration of illness was calculated as the number of days elapsed from first day
of febrile illness to the last day that a child reported any fever, muscle or joint
pain, headache, nauseas, vomiting, diarrhea, or any signs of bleeding or
hemorrhage.
**P-values were calculated using 2-way analysis of variance testing (ANOVA),
with a= 0.05 as the level of significance.
doi:10.1371/journal.pntd.0001311.t004
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for age, pre-infection DENV immunity, and epidemic year and
accounting for clustering of observations by school (data not
shown). The adjusted odds ratio was 1.70 (95% CI 1.15 to 2.51).
Discussion
The serological cross-reactivity between DENV serotypes is
well-documented and has been linked to both cross-protection and
enhanced disease. In contrast, the clinical implications of
serological cross-reactivity observed between DENV and other
non-DENV flaviviruses remain unclear. In this study, we
characterized the association between preexisting JEV antibodies
and the clinical severity of subsequent DENV infection in a
prospective study of school-children in Thailand. We report the
novel finding that JEV NAbs were associated with the increased
occurrence of symptomatic DENV infection.
The increased occurrence of symptomatic illness with preexist-
ing JEV NAbs was most pronounced in children who were
DENV-naı̈ve (i.e., presumably experiencing their first DENV
infection), for whom JEV NAbs were also associated with a longer
duration of illness. It is important to note that given the sensitive
method of identifying febrile illnesses in this cohort, ‘symptomatic
DENV illnesses’ ranged from a single day of fever to a prolonged
and debilitating disease course. It is therefore notable that we
observed an increase in the duration of illness in those with JEV
NAbs, suggesting that their influence was to increase the
occurrence and severity of clinically-meaningful DENV illness.
The significant findings in DENV-naı̈ve children are noteworthy
because in this group, JEV NAbs are more likely to reflect a ‘true’
prior exposure to JEV or JEV vaccine in this group and less likely
to have arisen as a cross reactive response to a prior DENV
infection. The association between JEV NAbs and symptomatic
illness was not as strong for DENV-monotypics and -multitypics,
which could be due to cross-protection with increasing DENV
immunity and/or a confounding effect with the inclusion of JEV
NAbs as a result of cross-reactivity.
Given the absence of confirmatory data from other human
cohorts or animal models, we must place these findings in the
context of prior in vitro investigations. This study may be most
analogous and in accordance with Putvatana et al, who found no
evidence of antibody-dependent enhancement of DENV-2
infection in vitro using sera of JEV-immune Thai individuals
[21]. We report an increase in non-hospitalized DENV illnesses
with preexisting JEV NAbs, but not DHF (in unadjusted analysis
and for nearly all subgroups), which may suggest that enhance-
ment is less likely to be the mechanism of increased DENV illness.
However, the number of DHF cases was low in this cohort study
and therefore the power to detect an association between JEV
antibodies and severe DENV illness was limited. It is also possible
that studies of this association, both in vivo and in vitro, could have
different conclusions based upon the serotypes and strains under
consideration [18]. Indeed, while only limited serotype-specific
analyses were possible with these data, the nature of the
association between JEV NAbs and hospitalized illness did not
appear to be consistent across serotypes. Finally, one important
caveat with this in vivo study is that while an association was
indeed detected between JEV NAbs and DENV illness, it is
possible that JEV NAbs are in fact a marker of another underlying
biological function that was not considered in this analysis, such as
cell-mediated immunity.
Notably, there was not a strong independent association in this
study between preexisting DENV immunity and the clinical
severity of a subsequent DENV infection; this may at first glance
appear to be in contrast to prior studies linking secondary DENV
infection with an increased occurrence of hospitalized illness or
DHF [36,37]. However, the present study uniquely focused on
predictors of symptomatic (primarily non-hospitalized) infection,
for which the influence of prior DENV exposures and DENV
immunity may be different. Second, while DENV-naives and
DENV-monotypics may be somewhat reliably characterized as
having no prior DENV infections and one prior DENV infection,
respectively, the DENV-multitypic group likely comprises a
Figure 2. Distribution of JEV neutralizing antibody titers among those with detectable JEV antibodies. Log10 titers are shown for
asymptomatic (dark gray) and symptomatic (striped) infections. JEV: Japanese encephalitis.
doi:10.1371/journal.pntd.0001311.g002
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mixture of children with multiple prior DENV infections as well as
children with a single prior DENV infection and a persistent cross-
reactive response. This ‘mixing of effects’ within the DENV-
multitypic group may have clouded the association between
DENV immunity and the clinical severity of DENV infection.
It is possible that some children were misclassified with respect
to pre-infection JEV serostatus in this study. The prevalence of
JEV NAbs in children experiencing DENV infection in the cohort
was 45%, remarkably low given that vaccine coverage was
estimated to exceed 80% at the time of the study. This low
seropositivity is likely due to waning of the antibody response,
which is a well-documented phenomenon with JEV inactivated
vaccines and particularly with the two-dose regimen [35,38]. 60%
of children who lacked JEV NAbs ‘seroconverted’ to become JEV
NAb positive in the post-season sample following a DENV
infection, which may reflect an anamnestic response to prior JEV
vaccination. Additionally, 76% of DENV-naı̈ve/JEV-negatives
exhibited a secondary-type response by ELISA during acute
infection, further suggesting that negative JEV and DENV
antibody titers do not preclude the possibility of a prior flavivirus
infection or JEV vaccination.
It is conceivable that different sources of JEV NAbs, which
could not be discerned in this study, may modulate the severity of
DENV infection in different ways. Given the cross-reactivity
between JEV and DENV in serological assays, it is possible that
JEV NAbs in some cases were present as a cross-reactive response
Figure 3. Associations between JEV neutralizing antibodies and clinical severity of DENV infections, by DENV serotype. The total
number of cases of non-hospitalized dengue fever (DF), hospitalized DF, and dengue hemorrhagic fever (DHF) are shown by dengue (DENV) serotype
(3a). The proportions of infections developing symptomatic illness (3b) and hospitalized illness (3c) are shown by Japanese encephalitis (JEV)
neutralizing antibody (NAb) status and infecting serotype. JEV NAb positive groups are represented by hash lines; JEV NAb negatives by white bars.
For figure 3b, the infecting DENV serotype was imputed for asymptomatic and RT-PCR-negative symptomatic infections, using information on the
predominate DENV serotype in circulation at a child’s school for the time interval during which they were infected, and restricting to those schools
that had only one serotype in circulation that year (as detected by RT-PCR). Analysis was restricted to RT-PCR-positive, and therefore symptomatic,
infections in figure 3c. Error bars indicate the 95% confidence interval for the proportion of children developing symptomatic illness (3b) and
hospitalized illness (3c).
doi:10.1371/journal.pntd.0001311.g003
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to a prior DENV infection. Further, while JEV vaccination was
widespread during the study period, wild-type JEV continued to
circulate and cause human infections. In summary, the JEV
antibodies detected in the cohort may have arisen as a result of
JEV vaccination, JEV infection, cross-reactivity from DENV
infection, or combinations of these. Future studies should seek to
distinguish between vaccine-derived JEV immunity and immunity
derived from natural exposure, perhaps by analysis of NS1-specific
antibodies [39].
The identification of asymptomatic DENV seroconversions
using sequential HI antibody data is a unique strength of this
study. However, it should be noted that the sensitivity of this
method to detect post-primary DENV infections, or DENV
infections in JEV immunes, has not yet been validated against a
gold standard. It is therefore possible that some DENV infections
were missed or misclassified as JEV infections (i.e., false negatives),
or that assay and/or biological variability caused an elevation of
HI titers where no new infection had in fact occurred (i.e., false
positives).
This first report of an association between preexisting JEV
NAbs and DENV illness warrants further study. Because this study
was conducted on a relatively limited temporal, spatial, and
demographic scale, similar analyses should be repeated in other
cohorts. It would be of particular interest to compare DENV-
endemic regions where live-attenuated and inactivated JEV
vaccines are in use. Possible associations between other flaviviruses
and DENV illness should be evaluated, and possible effect-
modifying effects of the infecting DENV serotype, should be
explored. It would be of great interest to investigate the association
between JEV cell-mediated immunity induced by JEV vaccination
and wild-type infection and the occurrence of DENV illness.
The biological mechanism of this association remains to be
elucidated. However, an intriguing mechanistic possibility may be
found in the literature surrounding other inactivated virus
vaccines. Some inactivated vaccines have been linked with
increased disease, perhaps due to the generation of an epitope-
restricted, lower titer immune response. Early efforts to develop
inactivated vaccines against measles and respiratory syncytial virus
were abandoned after they were linked with the occurrence of
atypical, occasionally severe disease [40,41] There have been no
reports to date of immuno-pathological responses following
inactivated flavivirus vaccination in humans, though a recent
study in mice reported that low doses of JEVAX were associated
with increased viral load and death following subsequent Murray
Valley encephalitis virus challenge, relative to placebo, high doses
of JEVAX, and the live Chimerivax-JEV vaccine [42].
In summary, we report that the prior existence of JEV NAbs
was associated with an increased probability of symptomatic
DENV illness in a cohort of school-children in Thailand. These
findings have public health importance in that DENVs co-
circulate with other flaviviruses in much of their geographic range
(e.g., JEV in Asia, yellow fever virus in Africa and South America,
and West Nile virus in various locations in both hemispheres) and
JEV vaccination is common throughout South and Southeast Asia.
We suggest that the issue of heterologous flavivirus immunity and
DENV, usually considered to be inconsequential or perhaps
protective, merits renewed interest and investigation. In particular,
the findings indicate that DENV vaccine developers should
include preexisting flavivirus immunity and vaccination histories
in assessments of vaccine safety and efficacy. The results of these
studies may be important for shaping DENV vaccine implemen-
tation strategies.
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